Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 8/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | AGXT | P21549 | 2/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30207605 | 1.00 | MIF (0.48) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| 3-Methoxybenxyl Isothiocyanate SCHEMBL1551644 | 0.77 | MIF (0.64) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL14382682 | 0.77 | CA12 (0.42) | ALDH1A1CA12CA1CA9HSP90AA1 | |
| SCHEMBL29975825 | 0.77 | CA12 (0.42) | TRPA1ALDH1A1CA12CA1CA9 | |
| SCHEMBL378877 | 0.77 | CA12 (0.42) | TRPA1ALDH1A1CA12CA1CA9 | |
| SCHEMBL4327915 | 0.76 | CA12 (0.44) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL558917 | 0.76 | CA12 (0.41) | ALDH1A1CA12CA1CA9HSP90AA1 | |
| SCHEMBL3866939 | 0.76 | MAOB (0.43) | CA12CA1CA9IDO1AGXT | |
| SCHEMBL559965 | 0.76 | KDR (0.41) | CA12CA1CA9HSP90AA1HSP90AB1 | |
| SCHEMBL29851528 | 0.76 | KDR (0.41) | CA12CA1CA9HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834417-B2 | Compositions for the treatment of hypertension and/or fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2023-12-05 | — | — | US | disclosed |
| CN-110234631-B | Composition for treating hypertension and/or fibrosis | 维克特斯生物系统有限公司 | 2023-02-28 | — | — | CN | disclosed |
| US-20210284612-A1 | Compositions for the Treatment of Hypertension and/or Fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2021-09-16 | — | — | US | disclosed |
| EP-3515895-B1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2021-08-11 | — | — | EP | disclosed |
| EP-3515895-B1 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2021-08-11 | — | — | EP | disclosed |
| US-11053202-B2 | Compositions for the treatment of hypertension and/or fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2021-07-06 | — | — | US | disclosed |
| EP-3640243-B1 | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2021-05-26 | — | — | EP | disclosed |
| EP-3640243-B1 | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS LTD (AU) | 2021-05-26 | — | — | EP | disclosed |
| US-20200255384-A9 | Compositions for the Treatment of Hypertension and/or Fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2020-08-13 | — | — | US | disclosed |
| EP-3640243-A1 | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | Vectus Biosystems Limited (AU) | 2020-04-22 | — | — | EP | disclosed |
| EP-3640243-A1 | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | Vectus Biosystems Limited (AU) | 2020-04-22 | — | — | EP | disclosed |
| EP-3515895-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | Vectus Biosystems Limited (AU) | 2019-07-31 | — | — | EP | disclosed |
| US-20190225588-A1 | Compositions for the Treatment of Hypertension and/or Fibrosis | VECTUS BIOSYSTEMS LTD (AU) | 2019-07-25 | — | — | US | disclosed |
| WO-2018053588-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | VECTUS BIOSYSTEMS LIMITED (AU) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284612-A1 | Compositions for the Treatment of Hypertension and/or Fibrosis | TGFB1, REN, TGFB2 | MIF 194/4885TRPA1 2574/4885ALDH1A1 1172/4885 |
| US-20200255384-A9 | Compositions for the Treatment of Hypertension and/or Fibrosis | TGFB1, REN, TGFB2 | MIF 194/4885TRPA1 2574/4885ALDH1A1 1172/4885 |
| US-20190225588-A1 | Compositions for the Treatment of Hypertension and/or Fibrosis | TGFB1, REN, TGFB2 | MIF 194/4885TRPA1 2574/4885ALDH1A1 1172/4885 |
| US-11834417-B2 | Compositions for the treatment of hypertension and/or fibrosis | TGFB1, REN, TGFB2 | MIF 194/4885TRPA1 2574/4885ALDH1A1 1172/4885 |
| US-11053202-B2 | Compositions for the treatment of hypertension and/or fibrosis | TGFB1, REN, TGFB2 | MIF 194/4885TRPA1 2574/4885ALDH1A1 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.